Cat. No. 3504
Chemical Name: P,P'-[1-Hydroxy-2-(3-pyridonyl)ethyl
Biological ActivityOrally active biphosphonate that inhibits farnesyl diphosphate (FPP) synthase (IC50 = 100 nM). Exhibits antiproliferative and proapoptotic activity in numerous tumor cell lines and inhibits osteoclast-mediated bone resorption in vivo.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Fournier et al (2008) Lowering bone mineral affinity of bisphosphonates as a therapeutic stragey to optimize skeletal tumor growth inhibition in vivo. Cancer Res. 68 8945. PMID: 18974139.
Stresing et al (2007) Bisphosphonates in cancer therapy. Cancer Letts. 257 16. PMID: 17697748.
Coxon et al (2006) Recent advances in understanding the mechanism of action of bisphosphonates. Curr.Opin.Pharmacol. 6 307. PMID: 16650801.
Dunford et al (2001) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J.Pharmacol.Exp.Ther. 296 235. PMID: 11160603.
If you know of a relevant reference for Risedronate please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Risedronate from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Risedronate, supplier, Farnesyl, diphosphate, FPP, inhibitors, inhibits, Synthases, Synthetases, Tocris Bioscience, Other Synthase/Synthetase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent farnesyl diphosphate (FPP) synthase inhibitorBz 423
ATP synthase inhibitor; proapoptotic
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.